[{"arm_notes": "", "treatment_id": null, "treatment_name": "initially; 30 patients with severe Covid-19 grade will be treated with intravenous administration of angiotensin- (1-7) for up to 7 days to assess the safety of this treatment (Phase I).If this step provides positive data; the second phase (Phase 2) will start. Patients with severe Covid -19 form will be divided into two groups. The experimental group (N = 50) had received intravenous angiotensin- (1-7) for up to 7 days. The second group will be treated with placebo; for the same period.Patients will be followed for up to 28 days.;Biological/vaccine;Other;D06.472.699.094", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": 85, "treatment_name": "Angiotensin 1-7", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "initially; 30 patients with severe Covid-19 grade will be treated with intravenous administration of angiotensin- (1-7) for up to 7 days to assess the safety of this treatment (Phase I).If this step provides positive data; the second phase (Phase 2) will start. Patients with severe Covid -19 form will be divided into two groups. The experimental group (N = 50) had received intravenous angiotensin- (1-7) for up to 7 days. The second group will be treated with placebo; for the same period.Patients will be followed for up to 28 days.;Biological/vaccine;Other;Angiotensins", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]